Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPI-145 monotherapy after progression in prior IPI-145-07 participants with CLL/SLL
2013-003639-31Phase 3Completed
- Sponsor
- Infinity Pharmaceuticals, Inc.
- Start
- Dec 2013
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of duvelisib and ofatumumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Infinity Pharmaceuticals, Inc. Primary endpoint: Overall Response Rate. Started Dec 2013; status: completed.
02
Drugs
duvelisibofatumumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2013-003639-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003639-31.